IN2014MN02330A - - Google Patents
Info
- Publication number
- IN2014MN02330A IN2014MN02330A IN2330MUN2014A IN2014MN02330A IN 2014MN02330 A IN2014MN02330 A IN 2014MN02330A IN 2330MUN2014 A IN2330MUN2014 A IN 2330MUN2014A IN 2014MN02330 A IN2014MN02330 A IN 2014MN02330A
- Authority
- IN
- India
- Prior art keywords
- cbp
- modulate
- activity
- compound
- electronegative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01048—Histone acetyltransferase (2.3.1.48)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/64—Screening of libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91051—Acyltransferases other than aminoacyltransferases (general) (2.3.1)
- G01N2333/91057—Acyltransferases other than aminoacyltransferases (general) (2.3.1) with definite EC number (2.3.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Computing Systems (AREA)
- Library & Information Science (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Evolutionary Biology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94540407P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/067477 WO2008157680A2 (en) | 2007-06-21 | 2008-06-19 | Methods and compositions for modulating p300/cbp activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02330A true IN2014MN02330A (enExample) | 2015-08-14 |
Family
ID=40156964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2330MUN2014 IN2014MN02330A (enExample) | 2007-06-21 | 2008-06-19 |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US8476458B2 (enExample) |
| IN (1) | IN2014MN02330A (enExample) |
| WO (1) | WO2008157680A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2441764B1 (en) * | 2009-06-12 | 2017-03-22 | Bioneer Corporation | Use of 4-methylenyl-5-oxo-1,5-dihydro-4H-pyrazol, 5-methylenyl-5H-cyclopenta[b]pyridine and pyrimidine-2,4,6(1H,3H,5H)-trione derivatives and related compounds for RNAase inhibition in RNA sample storage containers |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| CA2819829A1 (en) * | 2010-12-01 | 2012-06-07 | The Children's Hospital Of Philadelphia | Compositions and methods for treating foxp3+ treg related diseases |
| CN102180832B (zh) * | 2011-03-18 | 2012-09-12 | 苏州沪云肿瘤研究中心有限公司 | 脑缺血保护用化合物及制备方法 |
| WO2013026157A1 (en) * | 2011-08-24 | 2013-02-28 | Pharmagap Inc. | Anti-cancer peptides and uses thereof |
| WO2013033838A1 (en) * | 2011-09-09 | 2013-03-14 | Pharmagap Inc. | Liposomal formulations of cationic peptides and uses thereof |
| WO2013148114A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| CN105979958A (zh) * | 2013-10-11 | 2016-09-28 | 基因泰克公司 | Cbp/ep300布罗莫结构域抑制剂用于癌症免疫疗法的用途 |
| WO2015125956A1 (ja) * | 2014-02-24 | 2015-08-27 | 独立行政法人国立がん研究センター | p300を阻害する化合物によるがんの治療への応答性を予測する方法 |
| WO2017205503A1 (en) * | 2016-05-24 | 2017-11-30 | Indiana University Research And Technology Corporation | Ku inhibitors and their use |
| JP2019524740A (ja) * | 2016-07-25 | 2019-09-05 | エピザイム インコーポレイテッド | Crebbp関連癌の治療法 |
| CN108314652A (zh) * | 2017-01-18 | 2018-07-24 | 周意 | 依达拉奉衍生物及其用途 |
| WO2019055877A1 (en) | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| CA3075734A1 (en) * | 2017-09-19 | 2019-03-28 | Indiana University Research And Technology Corporation | Xpa inhibitor compounds and their use |
| IL279734B2 (en) | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| TW202102494A (zh) | 2019-03-15 | 2021-01-16 | 美商弗瑪治療公司 | 抑制環amp-反應元件-結合蛋白(creb) |
| CN110170052B (zh) * | 2019-06-21 | 2020-07-10 | 复旦大学 | Cbp-p300抑制剂在肠道损伤疾病中的应用 |
| WO2021119242A1 (en) | 2019-12-10 | 2021-06-17 | The Trustees Of Indiana University | Replication protein a (rpa)-dna interaction inhibitors |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US20240238426A1 (en) * | 2021-03-04 | 2024-07-18 | The Scripps Research Institute | Protein acylation modulation by heterobifunctional molecules |
| CN115124517B (zh) * | 2021-03-26 | 2024-06-18 | 复旦大学 | 芳香族化合物、其制备方法、药物组合物和应用 |
| WO2023205458A2 (en) * | 2022-04-21 | 2023-10-26 | The Regents Of The University Of California | Formulations for repelling bees and other insects |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030064426A1 (en) * | 2001-02-01 | 2003-04-03 | Jason Poole | Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors |
| US20070054278A1 (en) * | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| EP1718308A4 (en) * | 2004-02-11 | 2007-07-18 | Painceptor Pharma Corp | PROCESS FOR MODULATING NEUROTROPHINE-MEDIATED ACTIVITY |
| US20060084085A1 (en) * | 2004-06-16 | 2006-04-20 | Sinclair David A | Methods and compositions for modulating Bax-mediated apoptosis |
| WO2008067477A1 (en) | 2006-11-29 | 2008-06-05 | Wausau Paper Specialty Procucts, Llc | Non-slip masking product, and methods |
-
2008
- 2008-06-19 WO PCT/US2008/067477 patent/WO2008157680A2/en not_active Ceased
- 2008-06-19 US US12/665,751 patent/US8476458B2/en active Active
- 2008-06-19 IN IN2330MUN2014 patent/IN2014MN02330A/en unknown
-
2013
- 2013-05-30 US US13/905,222 patent/US9138439B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130345267A1 (en) | 2013-12-26 |
| WO2008157680A2 (en) | 2008-12-24 |
| WO2008157680A3 (en) | 2009-12-30 |
| US8476458B2 (en) | 2013-07-02 |
| US9138439B2 (en) | 2015-09-22 |
| US20100216853A1 (en) | 2010-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008157680A3 (en) | Methods and compositions for modulating p300/cbp activity | |
| TW200637866A (en) | Amino-imidazolones for the inhibition of β-secretase | |
| TN2009000182A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| TW200639166A (en) | Amino-pyridines as inhibitors of β-secretase | |
| WO2007139960A3 (en) | Compounds that modulate hsp90 activity and methods for identifying same | |
| DOP2006000051A (es) | Inhibidores de vegf-r2 y métodos | |
| PL1836169T3 (pl) | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek | |
| TN2009000255A1 (en) | Quinazolines for pdk1 inhibition | |
| MX2010005648A (es) | Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina. | |
| EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
| MX2010001565A (es) | Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90. | |
| MX2009008547A (es) | Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer. | |
| IN2012DN03883A (enExample) | ||
| TW200720268A (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| NZ602368A (en) | Iap bir domain binding compounds | |
| UA107796C2 (en) | Tetracyclic compound | |
| TW200738234A (en) | Triazole compounds that modulate HSP90 activity | |
| MX2009005795A (es) | Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona. | |
| GB2466912A (en) | Compositions and methods for treating lysosomal disorders | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| IL195341A (en) | A method of preparing simvastatin and compounds containing simvastatin | |
| EA200970349A1 (ru) | Ингибиторы металлопротеазы гетероциклического происхождения | |
| DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. |